Alyce Anderson1, Cynthia Cherfane2, Benjamin Click3, Claudia Ramos-Rivers4, Ioannis E Koutroubakis4, Jana G Hashash4,5, Dmitriy Babichenko6, Gong Tang7, Michael Dunn4, Arthur Barrie4, Siobhan Proksell4, Jeffrey Dueker4, Elyse Johnston4, Marc Schwartz4, David G Binion4. 1. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 2. Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA. 3. Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA. 4. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 5. Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos-Jbeil, Lebanon. 6. School of Information Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 7. School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: Inflammatory bowel disease (IBD) is associated with alterations of the innate and adaptive immune systems. Monocytes respond to inflammation and infection, yet the relationship between monocytosis and IBD severity is not fully understood. We aimed to characterize the prevalence of monocytosis in IBD and the association between monocytosis and disease severity and IBD-related health care utilization. METHODS: We used a multiyear, prospectively collected natural history registry to compare patients with IBD with monocytosis to those without monocytosis, among all patients and by disease type. RESULTS: A total of 1290 patients with IBD (64.1% with Crohn disease; 35.9% with ulcerative colitis) were included (mean age 46.4 years; 52.6% female). Monocytosis was found in 399 (30.9%) of patients with IBD (29.3% with Crohn disease; 33.9% with ulcerative colitis). Monocytosis was significantly associated with abnormal C-reactive protein level and erythrocyte sedimentation rate, anemia, worse quality of life, active disease, and increased exposure to biologics (all P < 0.001). Compared with patients without monocytosis, patients with monocytosis had a 3-fold increase in annual financial health care charges (median: $127,013 vs. $32,925, P < 0.001) and an increased likelihood of hospitalization (adjusted odds ratio [AOR], 4.5; P < 0.001), IBD-related surgery (AOR, 1.9; P = 0.002), and emergency department (ED) use (AOR, 2.8; P < 0.001). Patients with monocytosis had a shorter time to surgery, hospitalization, and ED visit after stratifying by disease activity (all P < 0.05). CONCLUSIONS: Patients with IBD with monocytosis, regardless of disease type, are at increased risk for worse clinical outcomes, hospitalization, surgery, and ED use. Peripheral monocytosis may represent a routinely available biomarker of a distinct subgroup with severe disease.
BACKGROUND: Inflammatory bowel disease (IBD) is associated with alterations of the innate and adaptive immune systems. Monocytes respond to inflammation and infection, yet the relationship between monocytosis and IBD severity is not fully understood. We aimed to characterize the prevalence of monocytosis in IBD and the association between monocytosis and disease severity and IBD-related health care utilization. METHODS: We used a multiyear, prospectively collected natural history registry to compare patients with IBD with monocytosis to those without monocytosis, among all patients and by disease type. RESULTS: A total of 1290 patients with IBD (64.1% with Crohn disease; 35.9% with ulcerative colitis) were included (mean age 46.4 years; 52.6% female). Monocytosis was found in 399 (30.9%) of patients with IBD (29.3% with Crohn disease; 33.9% with ulcerative colitis). Monocytosis was significantly associated with abnormal C-reactive protein level and erythrocyte sedimentation rate, anemia, worse quality of life, active disease, and increased exposure to biologics (all P < 0.001). Compared with patients without monocytosis, patients with monocytosis had a 3-fold increase in annual financial health care charges (median: $127,013 vs. $32,925, P < 0.001) and an increased likelihood of hospitalization (adjusted odds ratio [AOR], 4.5; P < 0.001), IBD-related surgery (AOR, 1.9; P = 0.002), and emergency department (ED) use (AOR, 2.8; P < 0.001). Patients with monocytosis had a shorter time to surgery, hospitalization, and ED visit after stratifying by disease activity (all P < 0.05). CONCLUSIONS: Patients with IBD with monocytosis, regardless of disease type, are at increased risk for worse clinical outcomes, hospitalization, surgery, and ED use. Peripheral monocytosis may represent a routinely available biomarker of a distinct subgroup with severe disease.
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Cynthia E Cherfane; Luke Gessel; Dominic Cirillo; Miriam B Zimmerman; Steven Polyak Journal: Inflamm Bowel Dis Date: 2015-08 Impact factor: 5.325
Authors: Peter Panizzi; Filip K Swirski; Jose-Luiz Figueiredo; Peter Waterman; David E Sosnovik; Elena Aikawa; Peter Libby; Mikael Pittet; Ralph Weissleder; Matthias Nahrendorf Journal: J Am Coll Cardiol Date: 2010-04-13 Impact factor: 24.094
Authors: A Schottelius; S Wedel; R Weltrich; W Rohde; F Buttgereit; S Schreiber; H Lochs Journal: Am J Gastroenterol Date: 2000-08 Impact factor: 10.864
Authors: Luis Chara; Ana Sánchez-Atrio; Ana Pérez; Eduardo Cuende; Fernando Albarrán; Ana Turrión; Julio Chevarria; Miguel A Sánchez; Jorge Monserrat; Antonio de la Hera; Alfredo Prieto; Ignacio Sanz; David Diaz; Melchor Alvarez-Mon Journal: Arthritis Res Ther Date: 2012-07-27 Impact factor: 5.156